chonthicha tanking

Dr. chonthicha tanking

chulabhorn hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
Alexios S AntonopoulosAlexios S Antonopoulos
Alexios S Antonopoulos
AAAlessia Azzu
Alessia Azzu
EAEmmanuel Androulakis
Emmanuel Androulakis
CTchonthicha tanking
chonthicha tanking
PPPanagiotis Papagkikas
Panagiotis Papagkikas
RMRaad H Mohiaddin
Raad H Mohiaddin
Aims : Eosinophilic heart disease (EHD) is a rare cardiac condition with a wide spectrum of phenotypes. The diagnostic and prognostic value of cardiac magnetic resonance (CMR) in EHD remains unknown. Methods and results : This was a retrospective analysis of 250 patients with eosinophilia referred for a CMR scan (period 2000–2020). CMR data sets and clinical/laboratory data were collected. Patients were followed up for a mean of 24 months (range 1–224) for the composite endpoint of death, acute coronary syndrome, hospitalization for acute heart failure, malignant ventricular arrhythmias, or the need for implantable cardiac defibrillator/pacemaker. The main objectives were to explore the diagnostic value of CMR in EHD; relationships between cardiac function, late gadolinium enhancement (LGE), and EHD phenotypes; and the prognostic value of fibrosis and oedema by CMR. The prevalence of findings compatible with EHD was 39% (patients with cardiac symptoms: 57% vs. screening: 20%, P < 0.001). EHD phenotypes included subendocardial LGE (n = 58), mid-wall/subepicardial LGE (n = 26), pericarditis (n = 5) or dilated cardiomyopathy (n = 8). Myocardial oedema was present in 10% of patients. Intracardiac thrombi (7%) were associated with EHD phenotype (χ2=47.3, P = 1.3×10−8). LGE extent correlated with LVEDVi (rho = 0.268, P = 5.3×10−5) and LVEF (rho=−0.415, P = 8.6×10−11). A CMR scan positive for EHD [hazard ratio (HR) = 5.61, 95% confidence interval (CI): 1.82–17.89, P = 0.0026] or a subendocardial LGE pattern (HR = 5.13, 95% CI: 1.29–20.38, P = 0.020) were independently associated with the composite clinical endpoint. Conclusion : The diagnostic yield of CMR screening in patients with persistent eosinophilia, even if asymptomatic, is high. The extent of subendocardial fibrosis correlates with LV remodelling and independently predicts clinical outcomes in patients with eosinophilia.

5 February 2024 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
CTchonthicha tanking
chonthicha tanking
CLChanokporn Lakkananurak
Chanokporn Lakkananurak
CSChaval Srisakvarakul
Chaval Srisakvarakul
AJAmaraluk Jitpreeda
Amaraluk Jitpreeda
KTKullisara Threechod
Kullisara Threechod
DSDamrong Sukitpunyaroj
Damrong Sukitpunyaroj
Background: Long‐COVID syndrome has become a new health concern. Many major clinical centers have experienced more patients with symptoms suggestive of autonomic dysfunction, especially postural orthostatic tachycardia syndrome (POTS) following COVID‐19. However, there is a lack of information regarding the incidence and associated factors in Asian population.Methods: A retro‐prospective study was conducted to evaluate patients with symptoms suggestive of POTS or other autonomic dysfunctions. These symptoms last at least 3 months after PCR‐proven COVID‐19. Exclusion criteria were age under 18 years old, pregnancy, and pre‐COVID‐19 autonomic dysfunction symptoms. Patients with a symptom severity score greater than two were assessed with blood tests, 24‐h Holter, 24‐h ambulatory blood pressure, echocardiogram, and head‐up tilt table (HUTT).Results: Seven hundred ninety‐three patients were interviewed at 146 ± 37 days after COVID‐19. The majority of patients were middle‐aged females (53%). Of those, 15 patients had the symptom severity score greater than 2. Out of those 15 patients, 12 had positive HUTT (1 demonstrating POTS, 10 neurocardiogenic syncope, and 1 orthostatic hypotension). Among those with positive HUTT patients, C‐reactive protein (CRP) was significantly higher (OR 1.01; p‐value 0.041). Fatigue and dyspnea on exertion were the two most complaint symptoms.Conclusions: This study shows the incidence of autonomic dysfunction and POTS is 1.5% (12/793) and 0.1% POTS (1/793), respectively, in a primary care setting (among general post‐COVID‐19 patients). The most common symptoms for these patients were fatigue and dyspnea.

23 August 2020 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
CTchonthicha tanking
chonthicha tanking
SRSupawat Ratanapo
Supawat Ratanapo
Background: Primary cardiac lymphoma is an extra-nodal non-Hodgkin’s lymphoma, which usually responds well to chemotherapy. The disease has high mortality rate unless it is recognized and treated in time. Tissue pathology is crucially the diagnosis gold standard for treatment plan. This is a case report of an elderly female who presented with a huge right-sided cardiac tumour obstructing tricuspid flow. Case summary: An 81-year-old Asian female presented with clinical right-sided heart failure. Echocardiogram showed a large mass compressing and obliterating the right atrium. Trans-jugular tissue biopsy was performed. Initial pathology report was consistent with an angiosarcoma, based on an expression of Fli-1 (Friend leukaemia virus integration 1) from immunohistochemical staining. She died shortly after refusal to surgery. Autopsy was performed with diagnosis change to a diffuse large B-cell lymphoma (DLBCL) after tissue pathology. Discussion: Primary cardiac lymphoma is extremely rare. Adequate tissue and proper immunohistochemical staining are mandatory for treatment plan. Besides an angiosarcoma, DLBCL should be considered in the differential diagnosis of Fli-1 positive tissue cardiac mass.

12 March 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
CTchonthicha tanking
chonthicha tanking
VLVaritta Lawsakul
Varitta Lawsakul

15 October 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMaethas Panyawongkhanti
Maethas Panyawongkhanti
PCPeerawat Chintrakulchai
Peerawat Chintrakulchai
CTchonthicha tanking
chonthicha tanking
WLWongsakorn Luangphiphat
Wongsakorn Luangphiphat
Background: Coronary microvascular dysfunction (CMD) is a complication of severe aortic stenosis. Its prevalence after transcatheter aortic valve implantation (TAVI) and prognostic significance are understudied, as are the post-TAVI trajectories of microvascular indices. Aims: The aims of this study were to determine the pooled prevalence of CMD, the influence of the diagnostic modality, the post-TAVI coronary flow reserve (CFR) and microvascular resistance changes, and the prognostic impact of baseline CMD on major adverse cardiovascular events (MACE) in patients with severe aortic stenosis undergoing TAVI. Methods: Five databases were searched from January 2010 to December 2025 for studies involving adults with severe aortic stenosis undergoing TAVI in which CMD was assessed by wire-based thermodilution, angiography-derived indices, Doppler measurements, or stress cardiac magnetic resonance. The risk of bias and certainty of evidence were assessed using the Newcastle–Ottawa Scale and GRADE, respectively. Random-effects meta-analyses (DerSimonian–Laird) pooled CMD prevalence (stratified by modality), CFR change (mean difference; before–after design), and prognostic hazard ratios (HRs). Change in microvascular resistance was synthesized narratively. The protocol was prospectively registered (PROSPERO: CRD42025143775) and reported per the PRISMA 2020 guidance. Results: Eleven primary studies were analyzed, 10 of which (n = 1,212) contributed to the prevalence analyses. An additional study (n = 126) was included in the sensitivity analyses only. CMD prevalence was 46.8% (95% confidence interval [CI] [34.0, 59.9]; I 2 = 72%) and 38.4% (95% CI [35.3, 41.7]; I 2 = 0%) when assessed using wire-based thermodilution (k = 6, n = 324) and angiographic (k = 4, n = 888) indices, respectively. CFR increased post-TAVI by a pooled mean difference of +0.49 (95% CI [+0.27, + 0.71]; I 2 = 72%; k = 5, n = 103 paired observations). Reductions in microvascular resistance were confined to pressure-to-velocity and reserve ratio indices, and absolute minimal microvascular resistance was unchanged (k = 4, n = 85). The HR for MACE was 3.22 (95% CI [0.98, 10.60]; I 2 = 78%; k = 2, n = 585). Substantial heterogeneity reflected non-equivalent CMD definitions. Conclusion: The prevalence of CMD pre-TAVI is influenced by the diagnostic method. CFR tends to improve after TAVI, likely due to reduced resting demand rather than structural repair. The CMD–MACE association should be viewed as hypothesis-generating due to limited studies, varied CMD definitions, and incompatible HR calculations. Prospective multicenter studies with standardized CMD definitions are required.

1 January 2024 in Journal of the Hong Kong College of Cardiology
Verified
Journal Article
Open access
PDF file
CTchonthicha tanking
chonthicha tanking
CWChanwit Wuttichaipradit
Chanwit Wuttichaipradit
CSChayanee Samdaengpan
Chayanee Samdaengpan
JSJomtana Siripaibun
Jomtana Siripaibun
RMR.N Siriwan Manahwan
R.N Siriwan Manahwan
VMViroj Muangsillapasart
Viroj Muangsillapasart
Background: According to the current guideline, statins should be provided to prevent anthracycline cardiotoxicity in high-risk cancer patients. This study aims to investigate the role of atorvastatin in preventing anthracycline-induced cardiac dysfunction among low-risk breast cancer patients. Methods: In this randomized, double-blinded, placebo-controlled trial, newly diagnosed breast cancer patients with low risk of cancer therapy-related cardiac dysfunction (CTRCD) were assigned to receive atorvastatin 40 mg or placebo. Echocardiography was performed before, at 3 and 6 months after the anthracycline treatment to determine changes in LVEF as a primary outcome. The secondary outcome included changes in global longitudinal strain (GLS), LV volume, high-sensitivity troponin T levels, the incidence of CTRCD and side effects from atorvastatin. Results: A total of 40 patients were enrolled. The post-anthracycline LVEF was significantly reduced compared with the baseline in both groups. The post-anthracycline LVEF reduction was lower in the atorvastatin group, however, not statistically significant (4% in the placebo group vs 2% in the atorvastatin group; p = 0.32). LV Volume, GLS, and troponin T levels did not change after anthracycline in both groups. The incidence of CTRCD was similar in both groups (3 (14%) in placebo, 3 (15%) in atorvastatin; p value 0.89) Conclusions: In low-risk breast cancer patients, atorvastatin does not show significant benefit in lessening the reduction of LVEF at 6 months post-anthracycline treatment. There were no differences observed in GLS changes, troponin levels, or the incidence of CTRCD between the atorvastatin and placebo groups.